Metformin in Diabetic Patients Undergoing Coronary Angiography

• Status: Recruiting
• Trial end date: 2021-09-01
• Target enrollment: 0
• Participant gender: All

Summary

The present study aims to evaluate the strict application of the 2018 European Society of Cardiology guidelines on myocardial revascularization, that recommends to check renal function if patients have taken metformin immediately before angiography and withhold metformin if renal function deteriorates.

The aim of this study is to assess the safety of metformin in diabetic patients undergoing coronary angiography in terms of risk of lactic acidosis and to individuate eventual predictors of augmented lactic acid after coronary angiography.

• Phase: Phase 4
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Humanitas Hospital, Italy
• Treatments: Metformin

Criteria

Inclusion Criteria:

• Diabetic patients treated with metformin undergoing coronary angiography.

Exclusion Criteria:

• Known coronary anatomy with planned complex percutaneous coronary intervention with high probability of large amount of contrast use (3.7 * estimated glomerular filtration rate; e.g.: 167 ml in a patients with an eGFR of 45 ml/min/1.73m2).

• Moderate to severe impairment of renal function (eGFR<45 ml/min).

• Moderate to severe impairment of liver function (Child-Pugh class B or C).

• Severely impaired left ventricular ejection fraction (LVEF <35%).

• Patients undergoing primary percutaneous coronary intervention (i.e., patients presenting with ST elevation myocardial infarction).

• Severe to very severe chronic obstructive pulmonary disease (GOLD class 3 to 4).

• Patients scheduled for cardiac surgery in the following 5 days.

• Inability to provide informed consent.